Related Experiment Videos
Rational use of measles, mumps and rubella (MMR) vaccine
1Fife Health Board, Glenrothes, Scotland.
Abstract:
Measles, mumps, rubella (MMR) vaccine is a live vaccine preparation containing attenuated strains of all 3 viruses. MMR vaccine is widely used throughout the world, with the US having the widest experience with the vaccine. In countries where the vaccine has been introduced successfully, significant reductions in all 3 diseases for which it is protective have occurred. The vaccine has been shown to be highly immunogenic, with seroconversion rates of 95 to 100% being achieved for each of the 3 component vaccines. This immunity appears to be long-lasting and may even be lifelong. Minor adverse effects may occur approximately 1 week after immunisation. Rarely, mumps vaccine-induced meningitis (milder than that associated with wild mumps virus) may occur, its frequency varying with the strain of attenuated mumps virus contained in any particular vaccine. Clinically, the vaccine is indicated for infants aged between 12 and 15 months, and should be administered by intramuscular or deep subcutaneous injection. A few specific contraindications exist, including a genuine hypersensitivity to eggs, and to the aminoglycoside antibiotics kanamycin and neomycin. An increasing number of countries are now adopting a 2-stage MMR policy in an attempt to prevent epidemics among those who remain unprotected, and to move towards eventual disease eradication.
Insights
The Measles, Mumps, and Rubella (MMR) vaccine offers robust, long-lasting protection against these three viral diseases. Widespread use has led to significant disease reduction, with high immunogenicity and rare adverse effects.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- The Measles, Mumps, and Rubella (MMR) vaccine is a live attenuated viral preparation.
- It is extensively used globally, with substantial experience in the United States.
- Successful implementation has resulted in significant declines in measles, mumps, and rubella incidence.
Purpose of the Study:
- To review the efficacy, safety, and administration guidelines of the MMR vaccine.
- To highlight the impact of MMR vaccination on disease prevalence.
- To discuss contraindications and evolving vaccination policies.
Main Methods:
- Review of existing literature on MMR vaccine efficacy and safety.
- Analysis of seroconversion rates and long-term immunity.
- Examination of reported adverse events and contraindications.
Main Results:
- MMR vaccine demonstrates high immunogenicity, achieving 95-100% seroconversion rates.
- Immunity conferred by the vaccine is generally long-lasting, potentially lifelong.
- Minor adverse effects are common, with rare instances of vaccine-induced meningitis.
Conclusions:
- The MMR vaccine is a safe and highly effective tool for preventing measles, mumps, and rubella.
- Adherence to recommended vaccination schedules and contraindications is crucial.
- Two-stage MMR policies are being adopted to enhance disease eradication efforts.